Pharsight

1. List of Abilify Maintena Kit drug patents

Application	Filing Date	Opposition Party	Legal Status
EP08000358A	2017-05-31	Teva Pharmaceutical Industries Ltd.	Revoked
EP08000358A	2017-05-31	Bülle Dr., Jan	Revoked
EP08000358A	2017-05-29	CHEMO IBERICA, S.A.	Revoked
EP08000358A	2017-04-10	Pharmaceutical Works Polpharma	Revoked
EP04002427A	2011-01-13	Teva Pharmaceutical Industries Ltd.	Patent maintained as amended
EP04795514A	2009-07-22	Alkermes, Inc.	Patent maintained as amended
EP02782507A	2007-01-05	Fermion Oy	Revoked
EP02782507A	2007-01-05	Pharmaceutical Works POLPHARMA	Revoked
EP02782507A	2007-01-05	EGIS Gyógyszergyár Nyrt	Revoked
EP02782507A	2007-01-05	Ratiopharm GmbH	Revoked
EP02782507A	2007-01-04	Teva Pharmaceutical Industries Ltd.	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US10525057	June, 2017	Decision	Raoufinia, Arash

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8993761	OTSUKA PHARM CO LTD	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Sep, 2022 (8 months ago)
US8399469	OTSUKA PHARM CO LTD	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Jun, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089567	OTSUKA PHARM CO LTD	Method of treating cognitive impairments and schizophrenias	Jan, 2022 (1 year, 4 months ago)
US8759351	OTSUKA PHARM CO LTD	Methods for administering aripiprazole	Aug, 2023 (2 months from now)
US8338428	OTSUKA PHARM CO LTD	Methods for administering aripiprazole	Aug, 2023 (2 months from now)
US8722679	OTSUKA PHARM CO LTD	Controlled release sterile injectable aripiprazole formulation and method	Oct, 2024 (1 year, 4 months from now)
US8030313	OTSUKA PHARM CO LTD	Controlled release sterile injectable aripiprazole formulation and method	Oct, 2024 (1 year, 4 months from now)
US7807680	OTSUKA PHARM CO LTD	Controlled release sterile injectable aripiprazole formulation and method	Oct, 2024 (1 year, 4 months from now)
US8338427	OTSUKA PHARM CO LTD	Methods for administering aripiprazole	Mar, 2025 (1 year, 9 months from now)
US11400087	OTSUKA PHARM CO LTD	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function	Sep, 2033 (10 years from now)
US10980803	OTSUKA PHARM CO LTD	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function	Sep, 2033 (10 years from now)
US11154553	OTSUKA PHARM CO LTD	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function	Sep, 2033 (10 years from now)
US11344547	OTSUKA PHARM CO LTD	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function	Sep, 2033 (10 years from now)
US10525057	OTSUKA PHARM CO LTD	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function	Mar, 2034 (10 years from now)

Do you want to check out ABILIFY MAINTENA KIT patents from before 2022?

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Tr...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
300 mg/vial and 400 mg/vial	20 Dec, 2021	1		24 Sep, 2033

Strength	Dosage	Availability
300MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
300MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription